These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26332562)

  • 1. Vasopressin Antagonists.
    Vandergheynst F; Gankam Kengne F; Decaux G
    N Engl J Med; 2015 Sep; 373(10):980-1. PubMed ID: 26332562
    [No Abstract]   [Full Text] [Related]  

  • 2. Vasopressin Antagonists.
    Berl T
    N Engl J Med; 2015 Sep; 373(10):981. PubMed ID: 26332561
    [No Abstract]   [Full Text] [Related]  

  • 3. Vasopressin antagonists.
    Berl T
    N Engl J Med; 2015 Jun; 372(23):2207-16. PubMed ID: 26039601
    [No Abstract]   [Full Text] [Related]  

  • 4. Vasopressin receptor antagonists: Characteristics and clinical role.
    Rondon-Berrios H; Berl T
    Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):289-303. PubMed ID: 27156765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pathway of vasopressin as a pharmacological target in nephrology: a narrative review].
    Recupero M; Fulignati P; Naticchia A; D'Alonzo S; D'Ascenzo F; Costanzi S
    G Ital Nefrol; 2018 Dec; 35(6):. PubMed ID: 30550035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin receptor antagonists in patients with chronic heart failure.
    De Vecchis R; Cantatrione C; Mazzei D
    Herz; 2017 Aug; 42(5):492-497. PubMed ID: 27628642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction: Vasopressin therapy.
    Whellan DJ
    Heart Fail Rev; 2009 Jun; 14(2):57-8. PubMed ID: 18989773
    [No Abstract]   [Full Text] [Related]  

  • 9. Vasopressin-receptor antagonists.
    Hoorn EJ; Zietse R
    Future Cardiol; 2010 Jul; 6(4):523-34. PubMed ID: 20608824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A; Menon MC
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of "Vaptans" in treatment of hyponatremia].
    Tanındı A; Töre HF
    Turk Kardiyol Dern Ars; 2015 Apr; 43(3):292-301. PubMed ID: 25906004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of hyponatremia.
    Gross P
    Semin Nephrol; 2001 May; 21(3):269-72. PubMed ID: 11320492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
    Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629
    [No Abstract]   [Full Text] [Related]  

  • 15. Vasopressin receptor antagonists.
    Greenberg A; Verbalis JG
    Kidney Int; 2006 Jun; 69(12):2124-30. PubMed ID: 16672911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
    Sánchez Sobrino P; Fernández Catalina P; Lorenzo Solar M; Rego Iraeta A
    Med Clin (Barc); 2015 Aug; 145(3):138-9. PubMed ID: 25543222
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).
    Harbeck B; Lindner U; Haas CS
    Endocrine; 2016 Sep; 53(3):872-3. PubMed ID: 26961548
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolvaptan efficacy and drug-drug interactions.
    Piccica M; Basile G; Bartalesi F; Parenti G; Farese A; Buci L; Corti G; Bartoloni A; Peri A
    Minerva Endocrinol; 2020 Sep; 45(3):264-265. PubMed ID: 32272825
    [No Abstract]   [Full Text] [Related]  

  • 19. Utility of Tolvaptan in the Perioperative Management of Severe Hyponatremia During Liver Transplantation: A Case Report.
    Parekh A; Rajaram P; Patel G; Subramanian RM
    Transplant Proc; 2017 Dec; 49(10):2399-2401. PubMed ID: 29198689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyponatremia: the role of lixivaptan.
    Liamis G; Filippatos TD; Elisaf MS
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):431-41. PubMed ID: 24766294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.